Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Emyria Ltd

EMD.AX ✓ COMPLIANT ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: N/A

Last Close

$0.03

▼ -2.22%

Market Cap $25.55M · Vol 438.07K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$25.55M

Micro Cap

Div Yield

0.00%

Annual dividend

EPS Growth

N/A

YoY

RSI (14)

44.44

Momentum

Beta

1.05

vs Market

52W High

$0.06

37.83% below

52W Low

$0.03

26.71% above

Volume

438.07K

Avg 1.07M

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

74.17%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Emyria Ltd (EMD.AX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does EMD.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-8.33%

-6.38%

-2.22%

-12.00%

YTD

-25.42%

-6.38%

-47.85%

-80.73%

Financials & Valuation

TTM · Annual

Total Revenue	$2.80M
Net Income	N/A
Revenue Growth (YoY)	+239.28%
Gross Margin	11.39%
Operating Margin	N/A
Net Profit Margin	-150.84%
ROE	N/A
ROA · ROIC	N/A · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	806.56M

Technical Indicators

50-Day SMA	$0.03
200-Day SMA	$0.04
RSI (14)	44.44
Beta	1.05
52-Week High	$0.06
52-Week Low	$0.03

Volume Today	438.07K
Avg Daily Volume (30D)	1.07M
Relative Volume	0.41x
Volatility (10D)	48.55
Volatility (30D)	58.37
Free Float	74.17%

Analyst Consensus

N/A

Current Price $0.03

Mean Target N/A

52W Low$0.03 52W High$0.06

Current

Target

$0.03 $0.06

Current Analyst target

· 0 analysts

Identifiers

ExchangeASX

FIGIBBG00R41CRB8

ISINAU0000073645

CountryAustralia

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LONN.S Lonza Group AG -2.54% RVMD Revolution Medicines Inc -0.40% ONC BeOne Medicines AG -1.22% 068270.KS Celltrion Inc +0.53% ABVX Abivax SA +0.66%

Company Profile

Emyria Limited is an Australia-based early-stage drug development company. The Company is focused on delivering and developing treatments for mental health and select neurological conditions, guided by real-world data collected with patients across its wholly owned clinical service subsidiaries. Its pipeline comprises MDMA analogue drug development and commercialization of novel serotonin-releasing agents. Its Emyria Healthcare provides evidence-based treatment for patients not finding relief from conventional care, while also helping evaluate emerging new therapies like assisted therapy for post-traumatic stress disorder (PTSD) and assisted therapy for treatment-resistant depression. Its Emyria Data is a robust and ethically sourced real-world data gathered with patients and used to improve its therapy and drug development programs. Its Emyria’s Pipeline includes new psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.